COMMUNIQUÉS West-GlobeNewswire

BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan
25/08/2026
— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to <12 years in Japan — RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, [...]
Apollo Therapeutics Announces Positive Immunogenicity Data and Cross-Species Activity from Phase 1 Trial of APL-10456, a Pan-Rhinovirus Vaccine for the Prevention of COPD Exacerbations
25/08/2026
Enrollment and dosing completed in Phase 1 randomized controlled trial (n=144) evaluating the safety, tolerability, immunogenicity and cross-species activity of APL-10456, an investigational rhinovirus vaccine Initial [...]
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
25/08/2026
All clinical trial sites identified and CRO retained Patient screening expected to begin in October 2026, with first patient to be enrolled shortly after FOSTER CITY, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Sagimet [...]
BrewDog Wins Big at the 2026 World Beer Awards with a Sweeping Show of Brewing Excellence
25/08/2026
Hazy Jane, Wingman and Mackie’s Two Scoops Earn Gold and Scotland Country Winner Awards, with Punk IPA, Lost Lager, Black Heart and Mello Also Recognised Among the World’s Best Beers ELLON, Scotland and LONDON, Aug. 25 [...]
Lumexa Imaging Announces Participation in Upcoming Investor Conferences
25/08/2026
RALEIGH, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging Holdings, Inc. (“Lumexa Imaging”) (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, announced today that Caitlin Zulla [...]
Aveanna to Participate in the 2026 Jefferies Healthcare Services and Technology Conference
25/08/2026
ATLANTA, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the 2026 Jefferies Healthcare Services and Technology [...]
Immatics Announces $150 Million Underwritten Offering
25/08/2026
Houston, Texas and Tuebingen, Germany, August 25, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell [...]
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
25/08/2026
BETHESDA, Md., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
25/08/2026
CAMBRIDGE, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by [...]
Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments
25/08/2026
Beyond Air to receive shares representing 19.99% of Univo's issued and outstanding share capital upon closing Beyond Air eligible to receive up to $32.5 million in development and commercial milestone payments GARDEN [...]
Astrocyte Pharmaceuticals Receives NIH Award to Evaluate AST-004 in Substance Use Disorders
25/08/2026
$400,000 program extends AST-004 into another major CNS indication and reinforces the breadth of its cerebroprotective potential GROTON, Conn., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Astrocyte Pharmaceuticals Inc. , a [...]
Trading in GN Store Nord shares by board members, executives and associated persons
25/08/2026
GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN [...]
Revier Therapeutics Launches with €6 Million Seed Financing to Pioneer Class IIa HDAC Inhibitors for Cardiometabolic Disease
25/08/2026
Heidelberg, Germany, August 25, 2026 – Revier Therapeutics (“Revier” or “the Company”), today announced the closing of a EUR 6 million seed financing and the launch of its operations. The Company has established the [...]
CDT Announces Investment in Pep'd, Expanding into the Fast-Growing US Peptide Market
25/08/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“ CDT ” or the “ Company ”), today announced that it has entered into a SAFE note with Pep'd Inc. (“ Pep'd [...]
Transactions in connection with share buy-back program
25/08/2026
Company announcement no. 32 - 26 25 August 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Trading by management and close relations of management
25/08/2026
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the [...]
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage
25/08/2026
NANJING, China, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that Opamtistomig (LBL-024), the Company’s proprietary PD-L1/4- [...]
Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules
25/08/2026
THE WOODLANDS, TX, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today [...]
Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics
25/08/2026
Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on [...]

Pages